Supplementary Table 1.

Patients deviating from the protocol

Center	Random number	Group	Gender	Age	Type	Detailed description
01	053	Trial	Male	77	Absence of primary end points	Death at the 70th day
01	054	Trial	Female	71	Absence of primary end points	No assessment of frequency response at 6-month
01	068	Trial	Male	57	Absence of primary end points	No assessment of frequency response at 6-month
01	069	Control	Male	64	Absence of primary end points	No assessment of frequency response at 6-month
01	101	Trial	Female	64	Absence of primary end points	No assessment of perception threshold immediately after operation
01	122	Control	Male	55	Absence of primary end points	No assessment of perception threshold immediately after operation
01	129	Trial	Male	76	Absence of primary end points	Death at the 68th day
02	179	Control	Female	74	Absence of primary end points	No assessment of perception threshold immediately after operation
02	191	Trial	Female	60	Absence of primary end points	No assessment of perception threshold immediately after operation
02	192	Control	Female	54	Absence of primary end points	No assessment of perception threshold immediately after operation
03	004	Control	Female	73	Absence of primary end points	No assessment of perception threshold immediately after operation
04	002	Trial	Male	60	Absence of primary end points	No assessment of perception threshold immediately after operation
04	015	Trial	Male	71	Absence of primary end points	No assessment of perception threshold immediately after operation
04	048	Trial	Male	79	Absence of primary end points	Death at the 162nd day
04	049	Control	Male	77	Absence of primary end points	No assessment of perception threshold immediately after operation
04	056	Trial	Male	51	Absence of primary end points	No assessment of perception threshold immediately after operation
04	100	Trial	Male	75	Absence of primary end points	No assessment of perception threshold immediately after operation
04	107	Control	Male	66	Absence of primary end points	No assessment of perception threshold immediately after operation
04	138	Trial	Male	71	Absence of primary end points	No assessment of perception threshold immediately after operation
05	021	Trial	Male	78	Absence of primary end points	No assessment of perception threshold immediately after operation
05	025	Control	Male	70	Absence of primary end points	No assessment of perception threshold immediately after operation
05	043	Trial	Male	74	Absence of primary end points	No assessment of perception threshold immediately after operation
05	052	Control	Male	81	Absence of primary end points	Death at the 62nd day
05	116	Trial	Male	76	Absence of primary end points	No assessment of perception threshold immediately after operation
06	203	Trial	Female	76	Loss of follow-up	6-month
06	223	Control	Female	82	Loss of follow-up	1-month
07	144	Control	Male	26	Absence of primary end points	No assessment of perception threshold immediately after operation
08	026	Trial	Male	26	Absence of primary end points	No assessment of perception threshold immediately after operation
08	040	Control	Male	81	Absence of primary end points	No perception threshold immediately after operation
08	135	Control	Male	33	Absence of primary end points	No assessment of perception threshold immediately after operation
08	178	Control	Male	56	Loss of follow-up	1-, 3-, and 6-month
08	189	Trial	Male	80	Loss of follow-up	6-month
09	038	Trial	Male	63	Absence of primary end points	Death at the 95th day
09	074	Control	Male	78	Absence of primary end points	No assessment of perception threshold immediately after operation
09	088	Trial	Male	50	Absence of primary end points	No assessment of perception threshold immediately after operation
09	098	Control	Male	56	Absence of primary end points	No assessment of perception threshold immediately after operation
09	175	Trial	Female	64	Absence of primary end points	No assessment of perception threshold immediately after operation
09	188	Trial	Male	84	Absence of primary end points	No assessment of perception threshold immediately after operation
09	195	Control	Male	69	Absence of primary end points	No assessment of perception threshold immediately after operation
09	089	Trial	Female	77	Loss of follow-up	3- and 6-month
09	168	Control	Female	82	Loss of follow-up	6-month
10	117	Trial	Male	43	Absence of primary end points	No assessment of perception threshold immediately after operation
10	133	Trial	Male	76	Absence of primary end points	Death at the 126th day
10	153	Control	Male	76	Absence of primary end points	No assessment of perception threshold immediately after operation
13	029	Control	Male	53	Absence of primary end points	No assessment of perception threshold immediately after operation
13	046	Trial	Male	67	Absence of primary end points	No perception threshold immediately after operation
13	104	Control	Female	52	Absence of primary end points	No assessment of perception threshold immediately after operation
13	216	Trial	Female	59	Absence of primary end points	No assessment of perception threshold immediately after operation
14	091	Trial	Female	64	Loss of follow-up	1-month
14	090	Control	Male	56	Absence of primary end points	No assessment of perception threshold immediately after operation
14	115	Control	Male	76	Absence of primary end points	Death at the 75th day
14	197	Control	Female	73	Absence of primary end points	No pace-making threshold at 6-month after operation; no assessment of frequency response at 6-month

Center - 01: The Second Affiliated Hospital of Zhejiang University School of Medicine; 02: The Affiliated Hospital of Qingdao University Medical College; 03: The First People’s Hospital of Hangzhou; 04: The First Affiliated Hospital of Lanzhou University; 05: The First Affiliated Hospital of Xi’an Jiaotong University; 06: Northern Jiangsu People’s Hospital; 07: The First Affiliated Hospital of Suzhou University; 08: The Second Affiliated Hospital of Nanchang University; 09: Bethune International Peace Hospital of the Chinese PLA; 10: The First Affiliated Hospital of Kunming Medical University; 13: Jilin Province People’s Hospital; 14: Tianjin Chest Hospital.